Pilot scheme reveals how much individual DNA impacts the effectiveness of medicine
The trial saw 2,200 adults undergo whole genome sequencing to analyse how their individual DNA responds to the likes of antibiotics and over-the-counter painkillers.
A staggering 99% showed a genetic variant that affects their sensitivity to certain medicines.
This could mean some drugs, including over-the-counter, everyday painkillers, antibiotics and other prescription medications, won't work for some people based on their individual DNA.
DNA could stop over-the-counter medicines working for some Brits
The blood test, part of Bupa's My Genomic Health scheme, also looked into their genetic risk of developing 36 preventable diseases, including cancers, heart conditions and type 2 diabetes.
It found 91% of participants were found to be at risk of developing a disease with genetic and lifestyle risk factors, such as fatty liver disease, breast cancer and certain heart diseases.
While 73% had multiple genetic variants that put them at raised risk of developing a condition that could be prevented or detected early, leading to better health outcomes, including the likes of high cholesterol, skin cancer and type 2 diabetes.
Of the participants, 49% were found to be carriers of a genetic variant that could lead to a raised risk of a certain condition in future generations.
How to get your own Medication Check
Following the successful pilot, Medication Check can now be purchased through Bupa and will also be available to more than three million of its customers as part of its workplace health scheme.
A saliva test will establish what medications are most likely to be effective, those with increased risk of adverse side effects, or ones that won't work for you at all.
When to see your GP about cancer
Dr Rebecca Rohrer, clinical innovation and genomics director for Bupa, said: 'We've long known that most medications only work for 30-50% of the population.
'However, this pilot has highlighted just how significantly individual genomes impact the effectiveness of medications in treating conditions.
'With more than half of us regularly taking a prescription medication and an increasing number affected by a chronic condition, it's crucial that people are prescribed the right medicine from the start, tailored to their unique genetic makeup.
'In the longer term, genomics is key to early detection and even preventing some illnesses altogether.'
After completing the at-home medication check, patients will be offered a GP consultation with the healthcare provider to review any medication identified in their genetic tests.
It comes as Bupa is about to introduce two new products to its My Genomic Health suite later this year that will help to prevent or detect illness earlier.
The DNA Health Check will give people early warning of an increased genetic risk of four different conditions - breast cancer, prostate cancer, type 2 diabetes and cardiovascular disease.
While the Advanced DNA Health Check will combine insights from medication, disease risk, carrier status and traits, and will look at the genetic risk of developing conditions such as heart disease, metabolic disease and 10 types of cancer.
Recommended reading:
Full list of the DWP benefits and pensions changes due this month
Freddie Flintoff praises NHS staff who cared for him after serious car crash
Insurance refuse to pay man 'paralysed for life' after horror accident abroad
Carlos Jaureguizar, CEO for Bupa Global, India & UK, said: 'Whole genomic sequencing is fundamentally changing our approach to healthcare, pivoting from treatment to prevention.
'It has the power to become a health passport that people can reference throughout their lives.
'We firmly believe genomics is the path to health innovation and prevention, reducing the nation's health burden and giving people personalised knowledge of their own genomic profile to live well for longer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
40 minutes ago
- Bloomberg
Ozempic Maker's Plight Shows Managing Markets Counts Too
Ozempic-maker Novo Nordisk A/S saw its shares take a record plunge last week, sending their peak-to-trough collapse to 70% and returning them to levels last seen in 2022. The Danish drug giant's purpose may be to improve people's lives, but investors' shrinking gains from its opening of the anti-obesity market matter too. Novo's blind spot has been failing to see its share price as an asset to manage — and exploit. For years, Novo had a relatively quiet life as one member of an insulin oligopoly alongside US peer Eli Lilly & Co. and France's Sanofi SA. While it wasn't a completely smooth ride — 2016 was dire — Novo has never seen operational and strategic challenges on the scale it's now facing. In developing Ozempic for diabetes and its sibling Wegovy for weight loss, the company suddenly found itself riding a tiger.
Yahoo
41 minutes ago
- Yahoo
Glyphosate ‘most effective method' for council's weedkilling
Glyphosate-based herbicides continue to be used for weedkilling, Caerphilly County Borough Council has said. The chemical has drawn controversy in recent years amid allegations about possible carcinogenic effects, which continue to be debated and challenged. In July 2020, a Caerphilly Council officer said the local authority would look at 'suitable alternatives' for weed treatments while using glyphosate. Five years on, a council spokesperson said Caerphilly 'continues to use glyphosate-based herbicides, which remain licensed in the UK until at least December 2026, pending further review'. The spokesperson said roadside weedkilling is conducted by a contractor using 'precision spraying technology'. This is 'currently the most effective method for treating weeds on roads and footpaths', and while 'alternatives exist, they have proven less effective at scale'. The council also uses glyphosate for countryside management, 'but only as a last resort to treat invasive species such as Japanese knotweed, himalayan balsam, and giant hogweed', the spokesperson explained. In 'some cases' it is also used in controlled areas for stump treatment or bracken control 'where other options are unavailable'. The spokesperson said the council 'remains committed to minimising chemical use where possible while maintaining safe and accessible public spaces'. The council also pointed to a 2022 weedkiller study run by Cardiff Council which trialled a 'highly-concentrated' vinegar, and a hot foam treatment, as possible alternatives to glyphosate. Following the study, the council said an independent scientific report concluded glyphosate was 'the most effective and sustainable weed control method currently available'. It was also the 'least expensive product tested and ranked highest for customer satisfaction', Cardiff Council said at the time.
Yahoo
43 minutes ago
- Yahoo
Gonorrhoea vaccination appointments open
A new vaccine against gonorrhoea will be rolled out in August following a rise in cases. The illness is the most common sexually transmitted infection in Northern Ireland It will not be available for everyone initially, the focus will be on gay and bisexual men who have a recent history of multiple sexual partners or have recently had a sexually transmitted infection (STI). England will also begin its vaccination roll out in August this year. The Joint Committee on Vaccination and Immunisation (JCVI) recommended roll out of the vaccine in November 2023 following an upsurge in gonorrhoea cases. Rachel Spiers, Immunisation and Vaccination Programme Manager at the PHA, said around eight out of 10 gonorrhoea infections occur in men. "Gay and bisexual men are most commonly affected, so by offering the vaccine to those most at risk it will not only help to protect them against the disease but will also help to reduce the spread," she added. The vaccine is an existing one for meningococcal B disease, called 4CMenB. The UK Health Security Agency (UKHSA) research shows that those who receive the jab could be protected from the STI by up to 40% and it could help tackle levels of antibiotic-resistant strains of the disease. The vaccine will be available through GUM clinics within regional Health and Social Care Trusts. Gonorrhoea diagnoses in NI have risen sharply since 2022. There were 1606 gonorrhoea diagnoses in 2022, which was two and a half times higher than the previous year, and this high level of gonorrhoea diagnosis was sustained in 2023. There was a small decline in 2024 to 1,208 cases, according to PHA data. What is gonorrhoea? Gonorrhoea does not always have symptoms, but they can include pain, unusual discharge, inflammation of the genitals and infertility. It is easily passed from person to person through unprotected sex. The infection can be passed from a pregnant woman to her baby, and without treatment, can cause permanent blindness for a newborn baby. It is not spread by non-sexual contact like hugging. It is not transmitted through surfaces and materials like toilet seats, towels, cups or plates. If you have had successful treatment for gonorrhoea before, you can still catch it again. Source: NHS.
